Science Explorer Back to mapMap
Institution · AVL (France)

Most cited papers from AVL (France)

What are the most cited papers from AVL (France)?

The most cited paper from AVL (France) is "Functional and physical interaction between Bcl‐XL and a BH3‐like domain in Beclin‐1" (Maria Chiara Maiuri, Gaëtane Le Toumelin, Alfredo Criollo et al., 2007), with 1,095 citations. Next come "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models" (1,079) and "The neurobiology and control of anxious states" (971).

Showing 50 of 60 papers. Every paper with more than 112 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Functional and physical interaction between Bcl‐XL and a BH3‐like domain in Beclin‐1 Maria Chiara Maiuri, Gaëtane Le Toumelin, Alfredo Criollo et al. · The EMBO Journal Open access 19 Apr 2007 1,095
2 The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models András Kotschy et al. · Nature Oct 2016 1,079
3 The neurobiology and control of anxious states Mark John Millan · Progress in Neurobiology Jun 2003 971
4 Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing Barry Boland, Wai Haung Yu, Olga Corti et al. · Nature Reviews Drug Discovery ReviewOpen access 17 Aug 2018 570
5 Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application Mark J. Millan · Pharmacology & Therapeutics May 2006 548
6 The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways Mark John Millan, Alain P. Gobert, Françoise Lejeune et al. · Journal of Pharmacology and Experimental Therapeutics Open access 19 Aug 2003 517
7 Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes Mark J. Millan, Lisa Maiofiss, Didier Cussac et al. · Journal of Pharmacology and Experimental Therapeutics Open access 2002 487
8 BH3-Only Proteins and BH3 Mimetics Induce Autophagy by Competitively Disrupting the Interaction between Beclin 1 and Bcl-2/Bcl-XL Maria Chiara Maiuri, Alfredo Criollo, Ezgi Tasdemir et al. · Autophagy Open access 16 Jul 2007 428
9 Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies Reuben Benjamin et al. · The Lancet Open access140 authors Dec 2020 375
10 Network‐based Approaches in Pharmacology Baptiste Boezio, Karine Audouze, Pierre Ducrot et al. · Molecular Informatics Open access 10 Jul 2017 374
11 Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat Alain P. Gobert, Jean‐Michel Rivet, Fran�oise Lejeune et al. · Synapse Jun 2000 339
12 (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. Robert D. Schreiber, Mauricette Brocco, Valérie Audinot et al. · Journal of Pharmacology and Experimental Therapeutics Apr 1995 301
13 Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors Mark J. Millan · Journal of Pharmacology and Experimental Therapeutics Dec 2000 287
14 Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo Mark John Millan, Anne Dekeyne, Alain P. Gobert · Neuropharmacology Jul 1998 285
15 The role of monoamines in the actions of established and “novel” antidepressant agents: a critical review Mark John Millan · European Journal of Pharmacology 18 Aug 2004 256
16 Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade Mark John Millan, Mauricette Brocco, Alain P. Gobert et al. · Psychopharmacology 30 Jul 2004 250
17 Conidial Hydrophobins ofAspergillus fumigatus Sophie Paris, Jean-Paul Debeaupuis, Reto Crameri et al. · Applied and Environmental Microbiology Open access Mar 2003 242
18 Dopamine D3 receptor antagonists as therapeutic agents Jeffrey N. Joyce, Mark John Millan · Drug Discovery Today Jul 2005 238
19 Autotaxin Is Released from Adipocytes, Catalyzes Lysophosphatidic Acid Synthesis, and Activates Preadipocyte Proliferation Gilles Ferry, Edwige Tellier, Anne Try et al. · Journal of Biological Chemistry Open access May 2003 234
20 Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site Yann Wallez, Francine Cand, Francisco H. Cruzalegui et al. · Oncogene 14 Aug 2006 232
21 An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy Mark John Millan · Neuropharmacology 11 Dec 2012 231
22 Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents Mark John Millan, Franćoise Lejeune, Alain P. Gobert · Journal of Psychopharmacology Mar 2000 230
23 N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives Mark John Millan · Psychopharmacology 10 Mar 2005 222
24 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain Anne Amphoux, Vincent Vialou, Eva Drescher et al. · Neuropharmacology Apr 2006 214
25 Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands Tangui Maurice, Brian Paul Lockhart · Progress in Neuro-Psychopharmacology and Biological Psychiatry 1997 211
26 Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release Alain P. Gobert, Jean‐Michel Rivet, Valérie Audinot et al. · Neuroscience Feb 1998 204
27 Integrins: Molecular targets in cancer therapy Gordon C. Tucker · Current Oncology Reports Apr 2006 204
28 Agonist and antagonist actions of yohimbine as compared to fluparoxan at ?2-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states Mark J. Millan, Adrian Newman‐Tancredi, Val�rie Audinot et al. · Synapse Open access Feb 2000 198
29 Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes Adrian Newman‐Tancredi, Didier Cussac, Yann Quentric et al. · Journal of Pharmacology and Experimental Therapeutics 2002 196
30 Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer Delphine Mérino et al. · Science Translational Medicine 2 Aug 2017 194
31 Glial D-Serine Gates NMDA Receptors at Excitatory Synapses in Prefrontal Cortex Pascal Fossat, Fabrice R. Turpin, Silvia Sacchi et al. · Cerebral Cortex Open access 20 Jun 2011 186
32 Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor Adrian Newman‐Tancredi, Didier Cussac, Valérie Audinot et al. · Journal of Pharmacology and Experimental Therapeutics 2002 182
33 Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity Benjamin Chanrion, Clotilde Mannoury la Cour, Federica Bertaso et al. · Proceedings of the National Academy of Sciences Open access 24 Apr 2007 181
34 Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia Donia M. Moujalled et al. · Leukemia Open access 10 Sep 2018 176
35 Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus Amélie Soumier, Mounira Banasr, Sylviane Lortet et al. · Neuropsychopharmacology Jul 2009 175
36 TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer Virginie Maire, Céline Baldeyron, Marion Richardson et al. · PLoS ONE Open access 20 May 2013 175
37 Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties Béatrice Guardiola-Lemaı̂tre, Christian de Bodinat, Philippe Delagrange et al. · British Journal of Pharmacology Open access 14 Apr 2014 175
38 Comparison of MF/UF pretreatment with conventional filtration prior to RO membranes for surface seawater desalination Anne Brehant, Véronique Bonnelye, M. Perez · Desalination Sep 2002 174
39 Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats Alain P. Gobert, Mark John Millan · Neuropharmacology Feb 1999 171
40 Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2‐adrenergic and serotonin2C receptors: a comparison with citalopram Mark John Millan, Alain P. Gobert, Jean‐Michel Rivet et al. · European Journal of Neuroscience Mar 2000 170
41 Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex David J. Watson, Florence Loiseau, Manuela Ingallinesi et al. · Neuropsychopharmacology Open access 26 Oct 2011 156
42 The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines Mark John Millan, Mauricette Brocco · European Journal of Pharmacology Feb 2003 151
43 Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members Tristan Gallenne, Fabien Gautier, Lisa J. Oliver et al. · The Journal of Cell Biology Open access 20 Apr 2009 146
44 Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5‐HT2A sites for PCP‐induced locomotion in the rat Mark John Millan, Mauricette Brocco, Alain P. Gobert et al. · European Journal of Neuroscience Dec 1999 139
45 Multiple alpha-2 adrenergic receptor subtypes. II. Evidence for a role of rat R alpha-2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline. Mark J. Millan, Karin J. W. Bervoets, Jean‐Michel Rivet et al. · Journal of Pharmacology and Experimental Therapeutics Sep 1994 138
46 The "selective" dopamine D 1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin 2C receptors Mark John Millan, Adrian Newman‐Tancredi, Yann Quentric et al. · Psychopharmacology Jun 2001 134
47 Potentiation of the Fluoxetine‐Induced Increase in Dialysate Levels of Serotonin (5‐HT) in the Frontal Cortex of Freely Moving Rats by Combined Blockade of 5‐HT1A and 5‐HT1B Receptors with WAY 100,635 and GR 127,935 Alain P. Gobert, Jean‐Michel Rivet, Laetitia Cistarelli et al. · Journal of Neurochemistry Mar 1997 134
48 Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the ‘atypical’ antipsychotics, clozapine and risperidone Rudy Schreiber, Mauricette Brocco, Mark J. Millan · European Journal of Pharmacology Oct 1994 129
49 Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors Sophie Maurel-Remy, Karin J. W. Bervoets, Mark John Millan · European Journal of Pharmacology Jul 1995 128
50 Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. Mark J. Millan, J.‐L. PEGLION, Joël Vian et al. · Journal of Pharmacology and Experimental Therapeutics Nov 1995 126

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.